• Molecular NameCephapirin
  • SynonymCefapirin; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Cefaprin; Cefaprin sodium; Cephapirin Sodium; Cephapirine
  • Weight423.47
  • Drugbank_IDDB00567
  • ACS_NO21593-23-7
  • Show 3D model
  • LogP (experiment)-1.15
  • LogP (predicted, AB/LogP v2.0)-0.42
  • pka2.15
  • LogD (pH=7, predicted)-4.19
  • Solubility (experiment)1.03 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.15
  • LogSw (predicted, AB/LogsW2.0)9.33
  • Sw (mg/ml) (predicted, ACD/Labs)0.13
  • No.of HBond Donors2
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds8
  • TPSA176.5
  • StatusFDA approved
  • AdministrationIntravenous, intramuscular
  • PharmacologyAn injectable, first-generation cephalosporin antibiotic.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding62.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMajor metabolite detected is desacetylcephapirin.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityRats exposed via the oral route to cephapirin displayed low acute toxicity (LD50 = 14000 mg/kg). The most common adverse reactions are hypersensitivity reactions and alterations to liver function. Evidence of white blood cell disorders and anaemia were noted in some subjects.
  • LD50 (rat)LD50 = 14000 mg/kg
  • LD50 (mouse)N/A